Compare BridgeBio Pharma Inc (BBIO) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs United Airlines Holdings Inc — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while United Airlines Holdings Inc trades at $121 (market cap $39.06B). The key difference: United Airlines Holdings Inc is far larger — about 2.4× BridgeBio Pharma Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, United Airlines Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | UAL | |
|---|---|---|
Market Cap | $16.46B | $39.06B |
Sector | Health | Industrials |
52-Week High | $90.17 | $136.11 |
52-Week Low | $44.81 | $84.57 |
Enterprise Value | $18.02B | $55.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
United Airlines (UAL) trades at $121.16, down 3.84% amid sector volatility, with strong fundamentals including a P/E of 10.84 and net income margin of 6.06%. Recent earnings beats and a bullish analyst consensus (66% buy ratings) support a $160.88 price target. Cash flow trends show operational strength despite net outflows, while technical indicators signal near-term support at $120.
Outlook remains positive with projected revenue growth to $60.5B in 2026, though risks include fuel cost spikes and competitive pressures. The stock offers value with low valuation multiples and consistent earnings outperformance, positioning it for recovery if macroeconomic headwinds ease.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
